Kornimate/medical-research-clean huggingface dataset:
uterine flushing with human chorionic gonadotrophin and unexplained infertility

Conditions: Unexplained Infertility

Summary: a prospective randomized study included 210 women with unexplained infertility subjected to combined ovarian stimulation and intrauterine insemination (iui). two equal groups. study group, subjected to uterine flushing with human chorionic gonadotropin (hcg) one day before iui and control group subjected to iui alone.

a prospective randomized study included 210 patients with unexplained infertility subjected to coupled ovarian stimulation and intrauterine insemination (iui). two equal groups. study group, subjected to uterine flushing with human chorionic gonadotropin (hcg) one day before iui and control group subjected to iui alone.

Eligibility criteria:
inclusion criteria: * unexplained infertility (ui) exclusion criteria: * body mass index (bmi) ≥35 kg/m2, * follicle stimulating hormone \>10 international unit /litter in early follicular phase, * diagnosed cause of infertility, menstrual cycle irregularity, * ovarian cysts, * sever cervical stenosis, * former iui, * ongoing pregnancy and * renal or hepatic diseases were all the exclusion criteria.
minimally invasive soft channel brain haemorrhage evacuation for acute basal ganglia haemorrhage-- large hemorrhage evacuation (miracle-l)

Conditions: Intracerebral Hemorrhage

Summary: to determine if minimally invasive soft channel brain hemorrhage evacuation (scmis), compared with any other neurosurgical technique that includes open craniotomy, small skull window microsurgery , and endoscopic surgery, is at least as effective ('not inferior') on poor clinical outcome of death or major disability (mrs scores 4-6) at 6 months in basal ganglia intracerebral hemorrhage (ich) of 30 \< volume ≤ 100 ml.


Eligibility criteria:
* inclusion criteria: 1. adults (18 - 80 years) ; 2. the clinical diagnosis is acute intracerebral hemorrhage, confirmed by imaging; 3. onset within 48 hours, and surgery can be initiated within 48 hours; 4. basal ganglia hemorrhage, with a bleeding volume of 30 \< volume ≤ 100 ml; 5. reduced level of consciousness (gcs 4-14); 6. pre-stroke mrs score≤1 points; 7. systolic blood pressure \<140 mmhg before randomisation; 8. availability of being able to receive either scmis or other neurosurgical technique; 9. informed consent obtain accordingly to local regulations. * exclusion criteria: 1. definite evidence the ich is secondary to a structural abnormality in the brain (eg arteriovenous malformation, intracranial aneurysm, tumour, trauma, cerebral venous thrombosis) or previous thrombolysis or neurointerventional surgery. 2. a high likelihood that the patient will not adhere to the study treatment and follow-up regimen. 3. platelet count \ 1.4.
generation of a surgical field in the left lateral decubitus position

Conditions: Esophageal Cancer; Thoracic Diseases

Summary: the generation of a good surgical field at the mid-lower mediastinum during thoracoscopic esophagectomy in the left lateral decubitus position is often complicated. the investigators developed a simple and useful technique for surgical field generation.


Eligibility criteria:
inclusion criteria: * patients who underwent thoracoscopic esophageal resection from april 2015 to december 2019 in our hospital. exclusion criteria: * patients who underwent open thoracotomy

Keywords: left decubitus position mid-lower mediastinum thoracoscopic esophagectomy
evaluation of fractional ablative laser treatment for skin conditions

Conditions: Skin Laxity

Summary: evaluate the safety and efficacy of the fractional ablative laser for treatment of skin laxity and tightening


Eligibility criteria:
inclusion criteria: 1. male or female subjects aged 18-85 years 2. fitzpatrick skin type i-vi 3. has visible skin laxity in the treatment region or has a scar 4. post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study (applicable to female subjects only) 5. willing to have digital imaging and measurements taken of the treatment area and agree to use for presentation, educational or marketing purposes 6. subject must be able to read, understand and sign informed consent form in english 7. must be willing to adhere to the treatment and follow-up schedule and post-treatment care instructions exclusion criteria: 1. participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study. 2. any type of prior cosmetic treatment to the target area at physicians' discretion 3. history of malignant tumors in the target area. 4. skin abnormalities in the target area, e.g., cuts, scrapes, wounds, large moles. 5. pregnant and/or breastfeeding (applicable to females only) 6. having an infection, dermatitis or a rash in the treatment area. 7. significant concurrent illness, such as diabetes mellitus, cardiovascular disease, e.g., uncontrolled hypertension or pertinent neurological disorders. 8. suffering from coagulation disorders or taking prescription anticoagulation medications. 9. history of keloid scarring, hypertrophic scarring or of abnormal wound healing. 10. history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications. 11. history of vitiligo, eczema, or psoriasis. 12. history of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen. 13. history of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer. 14. current smoker or history of smoking within 6 months of study participation. 15. as per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
efficacy of internet-delivered strengths use intervention

Conditions: Mental Health Wellness; Professional Burnout

Summary: the aim of the study will be to test the efficacy of a novel online-delivered gamification-based intervention for the identification, development, and use of strengths in the workplace. the program will be addressed to young employees and will have the aim of boosting their well-being and performance.


Eligibility criteria:
inclusion criteria: * not other than the age of the participants. exclusion criteria: * lack of internet access during the period of the implementation of the program (prescreened during enrolment). controlled variables: * participants levels of work engagement and work experience will be controlled for by stratified randomization. for each of the two factors we will created three strata (low level: lowest - 33rd percentile; moderate level: 34th - 66th percentile; high level: 67th percentile - highest), and the randomization will be applied for each stratum.
viscosupplementation in patients with hemophilic arthropathy

Conditions: Osteoarthritis; Hemarthrosis; Hemophilia A; Hemophilia B

Summary: hemophilia is a recessive x chromosome linked genetic disorder of blood coagulation that affects about one in every ten thousand people. hemarthrosis, which you can begin in childhood, promptly leads to degenerative changes of the articular cartilage which culminate in deformity and degenerative changes early, known as hemophilic arthropathy, which is the most common complication of hemophilia. aside administration of clotting factor, treatment should address the degenerative changes already present in patients joints. our objective is to evaluate the effectiveness of articular washing followed by infiltration with corticosteroids and hylan g-f 20, followed by a program of home exercises and/or academy as the previous level of hemophilia patients, in relation to pain relief, and improved function and quality of life.

hemophilia is a recessive x chromosome linked genetic disorder of blood coagulation that affects about one in every ten thousand people. there are two main types of hemophilia. hemophilia a or classical hemophilia corresponds to 80% of the cases, and is caused by a deficiency or change of factor viii. hemophilia b is caused by deficiency or amendment of factor ix, and represents about 20%. patients with hemophilia type a or b have the same clinical presentation. cases with moderate or severe hemophilia exhibit a tendency to spontaneous bleeding or after minimal trauma, being the joints the most frequent sites of hemorrhage. the joints most commonly affected are the knees, followed by the elbows, ankles, shoulders and hips. hemarthrosis, which you can begin in childhood, promptly leads to degenerative changes of the articular cartilage which culminate in deformity and degenerative changes early, known as hemophilic arthropathy, which is the most common complication of hemophilia. the hemophilic arthropathy is highly debilitating and consumes a large amount of resources for the treatment of hemophilic patients. currently, by the adequate administration of the clotting factor, the hemophilic patient has a life expectancy of next to normal. therefore other forms of treatment must be researched; they can be palliative or modifiers of the natural history of disease, to try to postpone the need for arthroplasty . our objective is to evaluate the effectiveness of treatment, consisting of articular washing followed by infiltration with corticosteroids and hylan g-f 20, followed by a program of home exercises and/or academy as the previous level of hemophilia patients, in relation to pain relief, and improved function and quality of life.

Eligibility criteria:
inclusion criteria: * patients with hemophilia a or b; * symptomatic arthropathy; exclusion criteria: * inadequate follow-up; * bleeding elsewhere as to not allow for functional evaluation; * complications of arthrocentesis (infection).

Keywords: osteoarthritis hemarthrosis hemophilia a hemophilia b viscosupplementation
efficacy study of diabetes group visits

Conditions: Diabetes Mellitus, Type 2

Summary: much evidence exists that new, more effective methods of delivering care to diabetics are necessary. in our current system of delivering care, diabetes care is often done in the context of multiple other issues addressed during a regular office visit. providers often lack the time to properly educate patients on diabetes self management topics. this project hopes to show that group visits can improve clinical outcomes, patient satisfaction, provider satisfaction, and patient's self management knowledge, while decreasing cost. this group visit method can make care more patient-centered and team based which is in alignment with our organization's goal of becoming a true patient centered medical home. if successful, this could expand to our other family medicine clinic sites and provide a valuable learning opportunity for the family medicine residents at ohsu. the investigators will first identify newly diagnosed diabetics (diagnosed within the last 12 months) at the south waterfront and gabriel park family medicine clinics using epic. the investigators will invite those diabetics identified from the south waterfront clinic to participate in 6 group visits that will follow a curriculum that the investigators created based on the national standards for diabetes self management education and the acp diabetes care guide. this curriculum will address basic pathophysiology of diabetes, the "abcs to better diabetic care" as defined by the acp diabetes care guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. this intervention group will be compared to a control cohort identified at the gabriel park clinic that will continue to receive standard diabetes care from their primary physician. the investigators will look at and compare clinical outcomes (hemoglobin a1c, blood pressure (bp), and ldl cholesterol levels), adherence to recommended preventive measures for diabetics (foot exams, eye exams, yearly microalbumin, and immunizations), patient and provider satisfaction, as well as cost. cost data will be collected using epic to look at the costs involved in group visits compared to the cost of delivering diabetic care through the standard individual medical appointment. the investigators may also use epic to look at utilization of specialty services, emergency room visits, and inpatient admissions and compared utilization across groups.


Eligibility criteria:
inclusion criteria: * diagnosis of diabetes mellitus, type 2 after 11/01/2010 * english speaking exclusion criteria: * dementia * unable to come to all 6 preschedule group visits

Keywords: diabetes group visit shared medical appointment
surgeon core-strengthening program as a modifier for exertion associated with vaginal surgery

Conditions: Musculoskeletal Pain; Musculoskeletal Injury

Summary: work-related musculoskeletal pain and injury is a growing concern in surgery. vaginal surgery has unique ergonomic risks, but no studies have addressed the potential for an exercise regimen to reduce physical strain by vaginal surgeons

surgical ergonomics is a burgeoning field, spurred by the recognition of the high prevalence of work-related musculoskeletal pain and injury in practicing surgeons including obstetrician/gynecologists. surgery is often a demanding physical task, and the muscles and joints that are stressed vary by the surgical approach. vaginal surgery has unique ergonomic challenges, particularly for assistants who may need to laterally bend their torsos to visualize the surgical field while still holding retractors. this is often a compromising physical position for the back, the shoulders, and sometimes the neck which increases the risk of acute or chronic musculoskeletal injury. the risk of injury can be thought of as a discrepancy between the demands of the task and the individual's physical capabilities. surgeons' injury risk may be decreased if their physical capabilities can be improved through exercise. most existing publications on surgical ergonomics have focused on raising awareness and on environmental changes such as optimizing surgeon posture during the case or introducing micro-breaks and stretching. few publications have assessed a structured exercise program with the goal of decreasing surgeon pain or fatigue during and after surgery. to our knowledge, no studies have addressed this in vaginal surgery.

Eligibility criteria:
inclusion criteria: participant: ob/gyn resident or urology resident or urogyn fellow or urogyn attending case: vaginal prolapse surgery \>2 hours in length exclusion criteria: participant: 1. actively in physical therapy 2. joint surgery or joint injury within last 12 weeks 3. pregnant 4. less than 6 weeks postpartum case: 1. vaginal surgery \<2 hours in length 2. non-prolapse vaginal surgery
hypoglycemia associated autonomic failure in type 1 diabetes mellitus

Conditions: Type 1 Diabetes

Summary: the purpose of this study is to determine what corticosteroid receptor (and the dose of) is responsible for cortisol inducing hypoglycemia associated autonomic dysfunction in type 1 dm. specifically, we aim to determine whether stimulating the type 1 corticosteroid receptor (via fludrocortisone), the type 2 corticosteroid receptor (via dexamethasone), or both causes hypoglycemia associated autonomic dysfunction in type 1 dm.


Eligibility criteria:
inclusion criteria: * 16 (8 males, 8 females) type 1 diabetic patients aged 18-45 yr. * hba1c \> 7.0% * had diabetes for 2-15 years * no clinical evidence of diabetic tissue complications * 16 (8 males, 8 females) healthy volunteers aged 18-45 yrs. * body mass index \< 27kg · m-2 exclusion criteria: * prior or current history of poor health * abnormal results following blood and physical examination * pregnancy

Keywords: hypoglycemia exercise corticosteroids
randomized clinical trial of donepezil for the treatment of mild cognitive impairment in parkinson's disease

Conditions: Parkinson Disease; Mild Cognitive Impairment

Summary: phase ii, multi-centric, randomized, double-blinded, placebo-controlled, parallel design clinical trial to evaluate the safety, tolerability and efficacy of donepezil in patients with mild cognitive impairment in parkinson's disease (pd-mci). a total of 120 patients with pd-mci will be randomized to 12 months of oral donepezil 10mg or matching placebo (1:1). primary and co-primary efficacy endpoints are cognitive and functional cognitive scales: pd-crs and pd-cfrs. secondary efficacy endpoints include: cognitive tests evaluating attention, executive functions, language, memory and visuospatial domain; mood, anxiety, and apathy scales; questionnaires to evaluate quality of life; and subjective impression scales. serum neurofilament light chain, genetic screening of gba, apoe and mapt, and magnetic resonance imaging will be performed in a subset of these patients. the study will be conducted in 20 different centers around spain. the movement disorders unit of the neurology department at sant pau hospital (barcelona, spain) will be the coordinating center.


Eligibility criteria:
inclusion criteria: * age 50-80 * pd diagnosis according to mds criteria * hoehn and yahr stage i-iii * persistent subjective cognitive complaints for at least 6 months * mds pd-mci level i and level ii criteria * persistent pd-mci for at least 3 months * stable dopaminergic treatment for at least 1 month exclusion criteria: * pd dementia criteria * severe motor complications * dbs or any brain condition that may be contributing to cognitive impairment * active psychosis, major hallucinations, hads ≥11, active impulse control disorder, or other active severe behavioral disorders. * treatment under anticholinergics, cholinergic enhancers, or neuroleptics. * history of symptomatic arterial hypotension. * hypersensitivity or intolerance to donepezil or any of the excipients * pregnancy * unstable medical or surgical condition * any other significant observation that, in the investigator's opinion, would contraindicate participation in the study.

Keywords: parkinson's disease-mild cognitive impairment (pd-mci) donepezil randomized clinical trial (rct)
optimise-ckd drug utilization

Conditions: Chronic Kidney Disease

Summary: this is a multi-national, observational study program using secondary data sources to address research questions related to 1) real-world dapagliflozin utilisation in ckd and potential for further utilisation, 2), the current ckd treatment landscape and 3) real-world effectiveness of dapagliflozin in ckd (pending feasibility assessment).

optimise-ckd is an observational study program using secondary data sources to address research questions related to 1) real-world dapagliflozin utilisation in ckd and potential for further utilisation, 2), the current ckd treatment landscape and 3) real-world effectiveness of dapagliflozin in ckd (pending feasibility assessment). primary objective: to characterize dapagliflozin 10mg utilisation in clinical practice, by describing treatment naïve patients who (1) are treated with dapagliflozin 10 mg and (2) who are eligible for ckd treatment with dapagliflozin but untreated. secondary objectives: to describe the current clinical landscape among incident ckd patients, by: 1. describing baseline demographic and clinical characteristics, drug utilization, and ckd treatment (raasi and dapagliflozin 10 mg) patterns; and 2. describing selected outcomes among overall, treated and untreated incident ckd patients. exploratory objectives: to assess the real-world effectiveness of dapagliflozin in ckd patients, pending feasibility.

Eligibility criteria:
inclusion criteria: * adult patients (aged ≥18 years) * chronic kidney disease (diagnosis code, uacr \>30mg/g or 2 egfr ≥90 days apart, second value ≥75ml/min/1.73m2) * ≥365 days continuous enrolment in database exclusion criteria: * history of type 1 diabetes, gestational diabetes or dialysis * history of dapagliflozin 10mg prescriptions before index date
nitazoxanide in patients with metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the aim of this study is to evaluate the potential efficacy and safety of nitazoxanide in patients with metastatic colorectal cancer.

globally, colorectal cancer (crc) is a major malignant tumor of the gastrointestinal tract which originates from epithelial cells of the colon and rectum. the efficacy of current cancer therapies is still limited by severe adverse effects on normal tissues and chemoresistance development. therefore, recent efforts have been focused on the repurposing of existing drugs with good safety profiles for cancer treatment. nitazoxanide (ntz) is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses. ntz inhibited the proliferation of crc cell lines at or below concentrations that normally exhibit anti-parasitic activity.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of stage iv (metastatic) crc. staging will be performed according to the american joint committee on cancer (ajcc) 8th edition and will be documented by all investigating parameters of metastatic crc 2. male or female patients with age range from 18-65 years old 3. women of childbearing age will be required to be on acceptable forms of contraception 4. no contraindication to chemotherapy (absence of myelosuppression) 5. performance status \< 2 according to the eastern cooperative oncology group (ecog) score 6. adequate liver function (alanine aminotransferase (alt) and aspartate aminotransferase (ast) \< grade 2) according to the national cancer institute-common terminology criteria for adverse events, version 5.0 (nci-ctcae v 5.0) 7. adequate renal function (estimated creatinine clearance (ecrcl), serum creatinine (scr) \< grade 2) according to nci-ctcae, v 5.0 8. adequate hematological parameters (hemoglobin, erythrocytes, platelets, leukocytes and absolute neutrophil count (anc) \< grade 2 according to nci-ctcae, v 5.0 exclusion criteria: 1. pregnant or lactating women 2. patients who have known allergy to nitazoxanide or its metabolites 3. patients with concurrent active cancer originating from a primary site other than the colon or rectum 4. patients who are receiving highly plasma protein-bound drugs or drugs with extensive hepatic metabolism such as; coumarin anti-coagulants, oral hypoglycemic drugs and anti-epileptic drugs

Keywords: nitazoxanide